Latest & greatest articles for naproxen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on naproxen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on naproxen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for naproxen

1. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care Full Text available with Trip Pro

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care To compare the effectiveness and safety of naproxen and low-dose colchicine for treating gout flares in primary care.This was a multicentre open-label randomised trial. Adults with a gout flare recruited from 100 general practices were randomised equally to naproxen 750 mg immediately then 250 mg every 8 hours for 7 days or low-dose colchicine 500 mcg three (...) times per day for 4 days. The primary outcome was change in worst pain intensity in the last 24 hours (0-10 Numeric Rating Scale) from baseline measured daily over the first 7 days: mean change from baseline was compared between groups over days 1-7 by intention to treat.Between 29 January 2014 and 31 December 2015, we recruited 399 participants (naproxen n=200, colchicine n=199), of whom 349 (87.5%) completed primary outcome data at day 7. There was no significant between-group difference

2019 EvidenceUpdates

2. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease Full Text available with Trip Pro

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened (...) carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score

2019 EvidenceUpdates

3. Naproxen

Naproxen Top results for naproxen - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for naproxen The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain Full Text available with Trip Pro

A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+methocarbamol.This was a randomized, double-blind, comparative effectiveness trial (...) conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients were given 14 tablets of naproxen 500 mg, to be used twice a day, as needed for low back pain. Additionally, patients were randomized to receive a 1-week supply of orphenadrine 100 mg, to be used twice a day as needed, methocarbamol 750 mg, to be used

2018 EvidenceUpdates

5. Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness

Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness | CADTH.ca Find the information you need Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Pre-Operative Naproxen for Gynecological Surgery: Clinical Effectiveness Published on: July 24, 2017 Project Number: RB1123-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What (...) is the clinical effectiveness of pre-operative administration of naproxen to reduce post-operative pain following gynecological surgery? Key Message No relevant literature was identified regarding the clinical effectiveness of pre-operative administration of naproxen to reduce post-operative pain following gynecological surgery. Tags cancer, neuroendocrine tumors, somatostatin, Tumour, Tumours, neuroendocrinology, somatuline, peptide receptor radiotherapy Files Rapid Response Summary of Abstracts Published

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. (Abstract)

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton-pump inhibitor (...) randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal bleeding within

2017 Lancet Controlled trial quality: predicted high

7. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. Full Text available with Trip Pro

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain.Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen. The goal of the trial was to assess the noninferiority of celecoxib with regard to the primary composite (...) outcome of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or nonfatal stroke. Noninferiority required a hazard ratio of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-treat population and of 1.40 or lower in the on-treatment population. Gastrointestinal and renal outcomes were also adjudicated.A total of 24,081 patients were randomly assigned to the celecoxib group (mean [±SD] daily dose, 209±37 mg), the naproxen

2016 NEJM Controlled trial quality: predicted high

8. Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. Full Text available with Trip Pro

Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. Dysmenorrhea is caused by the discharge of prostaglandins into the uterine tissue; therefore, non-steroidal anti-inflammatory drugs (NSAIDs) are the established initial therapy for dysmenorrhea. Dysmenorrhea therapy may include the administration of drug monotherapy or combination therapy. However, clinical scientific evidence on the efficacy (...) of medications with two or three drugs combined is scarce or nonexistent.To evaluate and compare the efficacy and safety of two oral fixed-dose combinations for the relief of the symptoms of primary dysmenorrhea among Mexican women. One of the combinations is widely used in Mexico (paracetamol, pyrilamine and pamabrom) and the selected comparison was a medication with naproxen sodium, paracetamol and pamabrom based on the pathophysiology of primary dysmenorrhea.This was a single-centre, double blind

2016 Medwave Controlled trial quality: uncertain

9. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. Full Text available with Trip Pro

Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. Low back pain (LBP) is responsible for more than 2.5 million visits to US emergency departments (EDs) annually. These patients are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opioids, or skeletal muscle relaxants, often in combination.To compare functional outcomes and pain at 1 week and 3 months after an ED visit for acute LBP among (...) patients randomized to a 10-day course of (1) naproxen + placebo; (2) naproxen + cyclobenzaprine; or (3) naproxen + oxycodone/acetaminophen.This randomized, double-blind, 3-group study was conducted at one urban ED in the Bronx, New York City. Patients who presented with nontraumatic, nonradicular LBP of 2 weeks' duration or less were eligible for enrollment upon ED discharge if they had a score greater than 5 on the Roland-Morris Disability Questionnaire (RMDQ). The RMDQ is a 24-item questionnaire

2015 JAMA Controlled trial quality: predicted high

10. Naproxen

Naproxen USE OF NAPROXEN IN PREGNANCY 0344 892 0909 USE OF NAPROXEN IN PREGNANCY (Date of issue: August 2013 , Version: 1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Naproxen is a non-steroidal anti-inflammatory drug used primarily (...) for the treatment of pain and inflammation in rheumatic disease and other musculoskeletal disorders. Few studies have specifically investigated the fetal risks of maternal naproxen use in pregnancy. Some studies on NSAIDs as a class have shown an association between use in pregnancy and an increased risk of cardiovascular defects in the offspring, as well as an increased risk of spontaneous abortion. Increased rates of orofacial clefts, cardiac defects and non-isolated anophthalmia/microphthalmia have been

2014 UK Teratology Information Service

11. Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine Full Text available with Trip Pro

Randomized Trial of Sumatriptan and Naproxen Sodium Combination in Adolescent Migraine Treatment of adolescent migraine remains a significant unmet medical need. We compared the efficacy and safety of 3 doses of sumatriptan and naproxen sodium (suma/nap) combination tablets to placebo in the acute treatment of adolescent migraine.This randomized, parallel group study in 12 to 17 year olds required 2 to 8 migraines per month (typically lasting >3 hours untreated) for ≥ 6 months. Subjects entered

2012 EvidenceUpdates Controlled trial quality: predicted high

12. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial Full Text available with Trip Pro

Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial The purpose of this study was to evaluate whether oral naproxen or transdermal estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system.We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use (...) . Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis.There were 129 women who were assigned randomly to naproxen (n = 42 women), estradiol (n = 44 women), or placebo (n = 43 women). The naproxen group was more likely to be in the lowest quartile of bleeding and spotting days compared with placebo (42.9% vs 16.3%; P = .03). In the multivariable analysis, the naproxen group had a 10% reduction in bleeding and spotting days (adjusted relative

2012 EvidenceUpdates Controlled trial quality: predicted high

13. Oxaprozin and Naproxen Sodium Postoperatively Reduce Pain After Removal of Impacted Third Molars

Oxaprozin and Naproxen Sodium Postoperatively Reduce Pain After Removal of Impacted Third Molars UTCAT873, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Oxaprozin and Naproxen Sodium Post-operatively Reduce Pain After Removal of Impacted Third Molars Clinical Question In adult patients having extraction of impacted third molars, do oxaprozin or naproxen prevent or reduce pain better than does placebo? Clinical Bottom (...) Line 1,200 mg oxaprozin or 550 mg naproxen sodium daily for one week reduce postoperative pain after extraction of impacted third molars better than does placebo, but do not exceed placebo for swelling. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Kara 2010 36 healthy adults 18-25 yrs RCT, double-blind, crossover Key results Both oxaprozin and naproxen sodium provided

2011 UTHSCSA Dental School CAT Library

14. Systematic review with meta-analysis: NSAID use associated with increased cardiovascular risk and death, but naproxen appears to be the least harmful

Systematic review with meta-analysis: NSAID use associated with increased cardiovascular risk and death, but naproxen appears to be the least harmful NSAID use associated with increased cardiovascular risk and death, but naproxen appears to be the least harmful | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here NSAID use associated with increased cardiovascular risk and death, but naproxen appears to be the least harmful Article Text

2011 Evidence-Based Medicine

15. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan Full Text available with Trip Pro

Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan Multiple parenteral medications are used to treat migraine and other acute primary headaches in the emergency department (ED). Regardless of specific headache diagnosis, no medication eliminates the frequent recurrence of primary headache after ED discharge. It is uncertain which medication primary headache patients should be given on discharge from an ED. The aim (...) of this study is to compare the efficacy of oral sumatriptan with naproxen for treatment of post-ED recurrent primary headache.This was a randomized, double-blind efficacy trial. We randomized patients to either naproxen 500 mg or sumatriptan 100 mg for headache recurrence after ED discharge. Patients were eligible if they received parenteral therapy for an acute exacerbation of a primary headache in the ED. Patients who met established criteria for migraine without aura were designated a priori

2010 EvidenceUpdates Controlled trial quality: predicted high

16. Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets

Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Vimovo (naproxen/esomeprazole magnesium) Delayed Release Tablets Company: Pozen Application No.: 022511 Approval Date: 4/30/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

17. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life (Abstract)

Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life To evaluate efficacy and tolerability of a single, fixed-dose tablet of sumatriptan 85 mg/naproxen sodium 500 mg (sumatriptan/naproxen sodium) vs placebo in migraineurs who had discontinued treatment with a short-acting triptan because of poor response or intolerance.Triptan monotherapy is ineffective or poorly tolerated in 1 of 3 migraineurs and in 2 of 5 migraine attacks. In April, 2008, the Food (...) and Drug Administration approved the combination therapy sumatriptan/naproxen sodium, developed specifically to target multiple migraine mechanisms. This combination product offers an alternative migraine therapy for patients who have reported poor response or intolerance to short-acting triptans.Two replicate, randomized, multicenter, double-blind, placebo-controlled, 2-attack crossover trials evaluated migraineurs who had discontinued a short-acting triptan in the past year because of poor response

2009 EvidenceUpdates Controlled trial quality: uncertain

18. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI (Abstract)

Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI In a multicentre study to explore the effects of licofelone as a disease-modifying osteoarthritis drug in comparison with naproxen in patients with knee osteoarthritis (OA), using MRI and x-ray examination.Patients with knee OA (n = 355) were randomised to receive either licofelone (200 mg twice (...) a day) or naproxen (500 mg twice a day). MRI and x-ray examinations were performed at baseline, 6 months (MRI only), 12 and 24 months. MRI was used to assess quantitatively changes in cartilage volume, and x-ray examinations (Lyon-Schuss) to measure changes in the mean and minimum joint space width (JSW) in the medial compartment. Questionnaires probing symptoms were completed. Data were presented as intention to treat (ITT) and according to protocol (ATP).Cartilage volume loss in the global joint

2009 EvidenceUpdates Controlled trial quality: uncertain

19. Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Full Text available with Trip Pro

Cognitive function over time in the Alzheimer`s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.Randomized, double-masked chemoprevention trial.Six US memory clinics.Men and women aged 70 years and older (...) with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.Seven tests of cognitive function and a global summary score measured annually.Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over

2008 EvidenceUpdates Controlled trial quality: predicted high

20. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine (Abstract)

Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine Research suggests treating a migraine at the first sign of pain increases the likelihood of the best clinical outcome.To investigate the efficacy and tolerability of a fixed-dose, single-tablet formulation of sumatriptan 85 mg, formulated with RT Technology, and naproxen sodium 500 mg (sumatriptan/naproxen) as early intervention acute therapy for migraine.Patients (aged 18 to 65 years (...) ) with International Headache Society-defined migraine with or without aura were enrolled in one of two identically designed, randomized, double-blind, parallel group, placebo-controlled studies. Patients treated a single migraine within 1 hour of onset of migraine head pain and while the pain was mild with either sumatriptan/naproxen or placebo. The primary efficacy measure was the percentage of patients who became pain-free 2 hours postdose.Intent-to-treat analyses consisted of 576 and 535 migraineurs. At 2

2008 EvidenceUpdates Controlled trial quality: predicted high